Search Results - "Frías, P"

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes by Frías, Juan P, Davies, Melanie J, Rosenstock, Julio, Pérez Manghi, Federico C, Fernández Landó, Laura, Bergman, Brandon K, Liu, Bing, Cui, Xuewei, Brown, Katelyn

“…This open-label, 40-week, phase 3 trial assessed the efficacy and safety of tirzepatide, a weekly dual glucose-dependent insulinotropic polypeptide and…”
Get full text

A comprehensive techno-economic assessment of the impact of natural gas-fueled distributed generation in European electricity distribution networks by Mateo, C., Frías, P., Tapia-Ahumada, K.

“…This paper combines three models:, an energy simulator (eQuest), the Distributed Energy Resources Customer Adoption Model (DER-CAM), and a Reference Network…”
Get full text

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial by Jastreboff, Ania M., Kaplan, Lee M., Frías, Juan P., Wu, Qiwei, Du, Yu, Gurbuz, Sirel, Coskun, Tamer, Haupt, Axel, Milicevic, Zvonko, Hartman, Mark L.

“…In this trial involving participants with obesity, 48 weeks of treatment with retatrutide, an agonist of the GIP, GLP-1, and GCG receptors, resulted in…”
Get full text

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial by Rosenstock, Julio, Wysham, Carol, Frías, Juan P, Kaneko, Shizuka, Lee, Clare J, Fernández Landó, Laura, Mao, Huzhang, Cui, Xuewei, Karanikas, Chrisanthi A, Thieu, Vivian T

“…Despite advancements in care, many people with type 2 diabetes do not meet treatment goals; thus, development of new therapies is needed. We aimed to assess…”
Get full text

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial by Frías, Juan P, Dr, Guja, Cristian, MD, Hardy, Elise, MD, Ahmed, Azazuddin, MD, Dong, Fang, PhD, Öhman, Peter, MD, Jabbour, Serge A, MD

“…Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce glycaemia and weight, and…”
Get full text

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial by Rosenstock, Julio, Frías, Juan P, Rodbard, Helena W, Tofé, Santiago, Sears, Emmalee, Huh, Ruth, Fernández Landó, Laura, Patel, Hiren

“…IMPORTANCE: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2…”
Get full text

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study by Guja, Cristian, Frías, Juan P., Somogyi, Aniko, Jabbour, Serge, Wang, Hui, Hardy, Elise, Rosenstock, Julio

“…Aims To compare the efficacy and safety of adding the glucagon‐like peptide‐1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with…”
Get full text

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial by Jabbour, Serge A, Frías, Juan P, Hardy, Elise, Ahmed, Azazuddin, Wang, Hui, Öhman, Peter, Guja, Cristian

“…Among patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin combination produced greater reductions in…”
Get full text

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial by Ludvik, Bernhard, Frías, Juan P, Tinahones, Francisco J, Wainstein, Julio, Jiang, Honghua, Robertson, Kenneth E, García-Pérez, Luis-Emilio, Woodward, D Bradley, Milicevic, Zvonko

“…Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce bodyweight in…”
Get full text

Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial by Jabbour, Serge A, Frías, Juan P, Ahmed, Azazuddin, Hardy, Elise, Choi, Jasmine, Sjöström, C David, Guja, Cristian

“…In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters…”
Get full text

Synthesis and Evaluation of Antimicrobial and Antibiofilm Properties of A‑Type Procyanidin Analogues against Resistant Bacteria in Food by Alejo-Armijo, Alfonso, Glibota, Nicolás, Frías, María P, Altarejos, Joaquín, Gálvez, Antonio, Salido, Sofía, Ortega-Morente, Elena

“…Natural A-type procyanidins have shown very interesting biological activities, such as their proven antiadherence properties against pathogenic bacteria. In…”
Get full text

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study by Jabbour, Serge A., Frías, Juan P., Guja, Cristian, Hardy, Elise, Ahmed, Azazuddin, Öhman, Peter

“…This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP) and triglycerides after 28 weeks’…”
Get full text

Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial by Frías, Juan P., Nakhle, Samer, Ruggles, James A., Zhuplatov, Sergey, Klein, Eric, Zhou, Rong, Strange, Poul

“…Aim To assess the effects of once‐weekly exenatide on 24‐hour glucose control and variability. Materials and methods This double‐blind, placebo‐controlled…”
Get full text

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial by Frías, Juan P., Hardy, Elise, Ahmed, Azazuddin, Öhman, Peter, Jabbour, Serge, Wang, Hui, Guja, Cristian

“…This analysis assessed whether responses with exenatide once weekly plus dapagliflozin (n = 231), exenatide once weekly alone (n = 230), or dapagliflozin alone…”
Get full text

Spatial Cox processes in an infinite-dimensional framework by Frías, María P., Torres-Signes, Antoni, Ruiz-Medina, María D., Mateu, Jorge

“…We introduce a new class of spatial Cox processes driven by a Hilbert-valued random log-intensity. We adopt a parametric framework in the spectral domain, to…”
Get full text

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy by Frías, Juan P., Maaske, Jill, Suchower, Lisa, Johansson, Lars, Hockings, Paul D., Iqbal, Nayyar, Wilding, John P. H.

“…Aim To report the results of a 104‐week extension to a 52‐week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat…”
Get full text

COVID-19 mortality analysis from soft-data multivariate curve regression and machine learning by Torres–Signes, Antoni, Frías, María P., Ruiz-Medina, María D.

“…A multiple objective space-time forecasting approach is presented involving cyclical curve log-regression, and multivariate time series spatial residual…”
Get full text

A spatial functional count model for heterogeneity analysis in time by Torres-Signes, Antoni, Frías, María P., Mateu, Jorge, Ruiz-Medina, María D.

“…A spatial curve dynamical model framework is adopted for functional prediction of counts in a spatiotemporal log-Gaussian Cox process model. Our spatial…”
Get full text

Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study by Ferrannini, Ele, Baldi, Simona, Frías, Juan P., Guja, Cristian, Hardy, Elise, Repetto, Enrico, Jabbour, Serge A., DeFronzo, Ralph A.

“…Aim To determine the effects of individual and combined therapies on plasma insulin, glucagon, β‐hydroxybutyrate (β‐OH) and associated metabolites. Materials…”
Get full text

Improvements in current European network regulation to facilitate the integration of distributed generation by Frías, P., Gómez, T., Cossent, R., Rivier, J.

“…This paper analyzes how traditional regulation of distribution system operators (DSO) has to be improved to accommodate higher levels of distributed generation…”
Get full text